BRIEF published on 04/07/2026 at 07:05, 6 months 16 days ago Aelis Farma Secures €458k Grant for Obesity Program France 2030 Aelis Farma Obesity Research CB1 Receptor Nouvelle-Aquitaine Grant
PRESS RELEASE published on 04/07/2026 at 07:00, 6 months 16 days ago Inside Information / Other news releases Aelis Farma receives €458k grant under France 2030 for obesity program development, reinforcing innovation potential in metabolism field Metabolic Diseases Grant France 2030 Obesity Aelis Farma
BRIEF published on 03/21/2026 at 10:10, 7 months 2 days ago Aelis Farma Advances Phase 2B Clinical Trial for Down Syndrome Treatment Clinical Trial CB1 Receptor AEF0217 Down Syndrome Adaptive Behavior
PRESS RELEASE published on 03/21/2026 at 10:05, 7 months 2 days ago Inside Information / Other news releases Aelis Farma initiates Phase 2B clinical trial with AEF0217 for Down syndrome cognitive impairments, recruiting in France, Italy, and Spain. A promising first-in-class CB1-SSi inhibitor treatment Phase 2b Aelis Farma AEF0217 Down Syndrome Cognitive Impairments
BRIEF published on 01/12/2026 at 07:35, 9 months 11 days ago Aelis Farma receives a favorable opinion from the EMA for AEF0217 in trisomy 21 EMA Aelis Farma AEF0217 Down Syndrome Pediatric Development
BRIEF published on 12/02/2025 at 07:05, 10 months 21 days ago Aelis Farma launches a Phase 2B clinical trial for AEF0217 in people with Down syndrome Clinical Trial Aelis Farma CB1-SSi AEF0217 Down Syndrome
BRIEF published on 09/25/2025 at 22:20, 1 year ago Availability of the 2025 half-year financial report by Aelis Farma Financial Report Biopharmaceuticals Aelis Farma Medical Innovations CB1-SSi
PRESS RELEASE published on 09/25/2025 at 22:15, 1 year ago Half yearly financial reports and audit reports/limited reviews / Terms of availability of the half-yearly financial report Aelis Farma announces availability of 2025 half-year financial report. Company specializes in CB1 receptor treatments for brain and peripheral diseases Financial Report Aelis Farma CB1 Receptor Brain Diseases Peripheral Diseases
BRIEF published on 07/31/2024 at 10:02, 2 years 2 months ago Aelis Farma successfully raises 4.5 million euros Euronext Paris Investors Fundraising Biopharmaceutical Aelis Farma
PRESS RELEASE published on 07/31/2024 at 09:57, 2 years 2 months ago Inside Information / Other news releases Aelis Farma successfully completes Reserved Offering, raising €4.5 million for drug development. CEO expresses gratitude to investors. New shares to be admitted for trading on Euronext Paris on Aug 2, 2024 Euronext Paris Capital Increase Drug Development Aelis Farma Reserved Offering
Published on 10/23/2026 at 02:20, 8 hours 54 minutes ago Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
Published on 10/22/2026 at 23:30, 11 hours 44 minutes ago Cypher Announces Subscription Receipt Offering
Published on 10/22/2026 at 22:30, 12 hours 44 minutes ago Unusual Machines to Announce Third Quarter 2026 Financial Results and Provide Corporate Update
Published on 10/22/2026 at 16:00, 19 hours 14 minutes ago Future Fuels Announces Closing of Brokered Offering for Gross Proceeds of C$6.6 Million
Published on 10/22/2026 at 14:30, 20 hours 44 minutes ago Unusual Machines Receives $16.9 Million Purchase Order from Powerus for American-Made Drone Components
Published on 10/23/2026 at 11:00, 14 minutes ago Annual General Meeting Approves Contribution: Innok Robotics on Course for the Public Capital Market
Published on 10/23/2026 at 10:18, 55 minutes ago Schirp Schjmidt-Morsbach Rechtsanwälte PartG: Investor Lawsuits in the Wirecard Case: Federal Court of Justice Dismisses EY from Model Proceedings The lead plaintiff’s attorneys welcome the decision
Published on 10/23/2026 at 10:05, 1 hour 9 minutes ago SINEXCEL Achieves IEC 62443-4-1 Certification for Cybersecurity Compliance
Published on 10/23/2026 at 09:00, 2 hours 14 minutes ago Municipality Finance issues a USD 135 million tap under its MTN programme
Published on 10/22/2026 at 18:00, 17 hours 14 minutes ago THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 17 hours 14 minutes ago bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
Published on 10/22/2026 at 18:00, 17 hours 14 minutes ago H1 2026: marked improvement in operating results
Published on 10/22/2026 at 17:47, 17 hours 27 minutes ago Aéroports de Paris SA - 2026 9-month revenue
